Regulating Payment of Participant Data in Clinical Trials

Key Takeaways

• FMV payment for data proposed as regulatory standard
• Current participant pay averages $4,000 annually
• Data compensation could boost trial recruitment and retention
• Fair payments aim to increase demographic diversity
• FDA and IRBs must issue new guidance

Summary

A team of scholars led by Steve Calandrillo proposes that FDA and IRBs adopt fair‑market‑value (FMV) payments for the data participants generate in clinical trials. Currently, participants receive modest compensation—about $4,000 per year—solely for trial involvement, not for the valuable health data they provide. The authors argue that compensating data would improve recruitment, retention, and especially the demographic diversity of trial cohorts. They call for new regulatory guidance to formalize data‑based payments, suggesting that such reforms could accelerate drug development while enhancing equity.

Pulse Analysis

Clinical trials have long relied on modest participant stipends to offset time and inconvenience, yet the data harvested—often the cornerstone of billion‑dollar drug pipelines—remains uncompensated. This imbalance raises ethical concerns, especially as digital health tools amplify the volume and sensitivity of information collected, increasing privacy risks without corresponding financial recognition. By highlighting the $4,000 average annual payment, the authors underscore a stark disparity between the economic worth of trial data and the modest rewards offered to volunteers.

Calandrillo’s proposal to apply fair‑market‑value pricing to participant data reframes compensation as a market transaction rather than a charitable gesture. Aligning payments with data quality, invasiveness, and risk could make trials more attractive to underrepresented groups, addressing longstanding FDA diversity shortfalls. Monetary incentives tied to data ownership are likely to boost enrollment and reduce dropout rates, as participants weigh tangible returns against the costs of participation. Moreover, a structured FMV framework could standardize negotiations between sponsors and sites, fostering transparency across the industry.

Realizing this vision hinges on coordinated regulatory action. The authors call for the FDA to issue guidance that explicitly permits FMV data payments, with IRBs tasked with enforcing fairness under existing “just and fair” standards. If adopted, such policies could shorten development timelines by filling enrollment gaps more quickly and improving the external validity of trial outcomes. Beyond pharmaceuticals, the shift may set a precedent for data‑centric compensation models across biomedical research, reinforcing ethical stewardship of participant contributions while unlocking new efficiencies for innovators.